Gastroparesis Treatment Market Trends

Gastroparesis Treatment Market Overview

The Gastroparesis Treatment Market size was valued at USD 4184.83 million in 2024 and is expected to reach USD 5090.29 million by 2033, growing at a CAGR of 2.2% from 2025 to 2033.

The gastroparesis treatment market is defined by a growing global patient pool, increasing clinical diagnosis rates, and expanding treatment interventions. Gastroparesis, characterized by delayed gastric emptying without mechanical obstruction, affects approximately 5.1 million people globally, with the highest prevalence in diabetic populations. Among type 1 and type 2 diabetes patients, gastroparesis is diagnosed in 25.3% and 13.6% respectively. In the United States alone, over 1.9 million people suffer from diagnosed gastroparesis.

The demand for gastroparesis treatment has been driven by increasing hospitalization rates, which rose to 31.6 hospitalizations per 100,000 persons in North America in 2023. Drug therapy dominates the treatment landscape, accounting for 68.2% of primary interventions, while surgical options represent 17.4% of cases. Diagnostic improvements, including gastric emptying scintigraphy used in over 55% of new diagnoses, have contributed to higher identification rates of idiopathic and diabetic gastroparesis. North America leads the global market, followed by Europe and Asia-Pacific. In 2023, over 480,000 prescriptions for prokinetic agents such as metoclopramide and domperidone were issued globally, while surgical procedures such as gastric electrical stimulation were performed in over 12,000 patients. The total number of newly treated cases crossed 310,000 globally in 2023, underlining the importance of therapeutic accessibility and innovation in this segment.

Key Findings

Driver: Increasing diabetic population and complications; gastroparesis affects 25.3% of type 1 and 13.6% of type 2 diabetic patients globally.

Country/Region: North America leads the market, with over 1.9 million diagnosed gastroparesis cases as of 2023.

Segment: Drug treatment dominates the market with 68.2% of treatment methods, especially prokinetic and antiemetic therapies.

Gastroparesis Treatment Market Trends

The gastroparesis treatment market has shown a consistent shift in recent years toward improved pharmacological regimens, increasing surgical procedures, and enhanced diagnostic technologies. As of 2023, there were over 5.1 million individuals affected by gastroparesis worldwide, with the highest prevalence seen in patients with poorly controlled diabetes. Among diabetic patients, gastroparesis is seen in up to 25.3% of type 1 cases and 13.6% of type 2 cases. An estimated 460,000 new cases were identified globally in 2023. One of the primary trends in the gastroparesis treatment market is the adoption of prokinetic drugs such as metoclopramide, erythromycin, and domperidone. Prokinetic prescriptions totaled 480,000 globally in 2023. Metoclopramide, the most prescribed drug for gastroparesis, was used by 62.5% of diagnosed patients. Meanwhile, erythromycin prescriptions rose by 18% year-over-year due to its enhanced use in refractory cases.

Antiemetics also remain crucial in symptom control, particularly for nausea and vomiting, used in 36.4% of active treatments. Ondansetron and promethazine are among the top antiemetics used, accounting for 65,000 and 48,000 prescriptions respectively in 2023. Meanwhile, tricyclic antidepressants and narcotic-sparing pain medications are being increasingly applied in functional subtypes. Surgical procedures are also gaining traction. Gastric electrical stimulation (GES) procedures crossed 12,000 surgeries in 2023. This reflects a 22% rise compared to 2022, driven by improvements in implantation techniques and better insurance coverage in North America and parts of Europe. Other procedures like pyloroplasty and venting gastrostomy were performed in 8,600 and 4,200 patients, respectively, with success rates exceeding 78% in symptom resolution over 6 months. The role of diagnostic technology continues to evolve. Gastric emptying scintigraphy remains the gold standard, used in 55% of diagnoses, while breath tests and wireless motility capsules gained ground in 16% of new diagnostic procedures. Digital gastric mapping platforms and electrogastrography are emerging in research applications, with over 180 clinical trials globally exploring diagnostics and new treatment regimens. Emerging trends also include the development of combination therapies, non-pharmacological dietary approaches, and AI-assisted symptom monitoring tools. Over 22 digital health solutions specific to gastrointestinal motility disorders were in clinical validation stages as of late 2023. These tools aim to reduce symptom burden, improve adherence, and enhance personalized treatment outcomes for over 310,000 patients undergoing treatment annually.

Gastroparesis Treatment Market Dynamics

DRIVER

Rising prevalence of diabetes and gastrointestinal disorders

The growing number of diabetes cases worldwide is the primary driver of the gastroparesis treatment market. As of 2023, there were over 537 million people with diabetes globally, with projections indicating this number will exceed 643 million by 2030. Among these patients, approximately 15%–25% are likely to experience gastroparesis symptoms. In the United States, 1.9 million individuals live with diagnosed gastroparesis, and 78% of these patients have diabetes as an underlying cause. Additionally, 33% of newly diagnosed idiopathic cases have shown a link with viral or post-surgical triggers. With gastrointestinal complaints accounting for over 5.6 million outpatient visits in North America annually, the demand for targeted treatments has surged. Advancements in diagnostic accuracy and increased physician awareness are also expanding early treatment interventions.

RESTRAINT

Limited therapeutic options and adverse drug effects

Despite advancements, treatment options for gastroparesis remain limited. Currently, only a small number of drugs are approved for use, with metoclopramide accounting for over 62.5% of prescriptions globally. However, this drug carries a black box warning for tardive dyskinesia, a side effect occurring in less than 1% but posing long-term risks. Domperidone, another widely used agent, is not FDA-approved in the U.S., reducing availability in key markets. Additionally, erythromycin shows reduced efficacy with long-term use due to tachyphylaxis in more than 55% of patients. These limitations affect treatment compliance and increase the likelihood of repeated hospitalizations. Hospital readmission rates for severe gastroparesis cases stand at 28% within 90 days. Furthermore, gastric electrical stimulation devices have complication rates of 8.7%, with lead migration and infections requiring surgical revision.

OPPORTUNITY

Growth in personalized medicine and combination therapy

A major opportunity lies in the development of personalized medicine strategies and combination therapies. Recent studies show that combining prokinetics with antiemetics or neuromodulators improves symptom control in 42% of refractory cases. There are over 120 clinical trials globally investigating novel therapeutic combinations, with a significant focus on botulinum toxin pyloric injections and ghrelin receptor agonists. Non-invasive neuromodulation techniques, including transcutaneous electrical nerve stimulation, have been trialed in 15,000 patients, showing a 26% reduction in bloating and nausea. Nutritional interventions using elemental diets and blended feeding tubes have also shown benefits in 60% of moderate to severe cases. The pipeline for new drugs includes over 14 molecules in phase II or III development, offering potential breakthroughs by 2026. With over 22 million people potentially affected globally, especially in diabetic and post-surgical populations, customized care pathways will help reduce the overall disease burden.

CHALLENGE

Rising hospitalization and healthcare system costs

Rising hospitalization rates and treatment costs represent key challenges. In 2023, there were over 83,000 hospitalizations for gastroparesis in the U.S. alone, costing an estimated average of USD 8,500 per admission. The average hospital stay duration was 5.2 days, with intensive cases requiring stays of up to 14 days. Emergency department visits related to gastroparesis symptoms reached 124,000 in the same year, placing increased pressure on healthcare infrastructure. Furthermore, delayed diagnoses remain prevalent, with an average of 2.3 years from symptom onset to confirmed diagnosis. Many patients undergo unnecessary procedures, including endoscopies and imaging, leading to an estimated 21% increase in pre-treatment diagnostic expenses. In developing regions, limited access to advanced diagnostics and surgical options hampers early intervention, leaving nearly 40% of diagnosed cases untreated or poorly managed.

Gastroparesis Treatment Market Segmentation

The gastroparesis treatment market is segmented based on treatment type and application. Each segment reflects the unique demands of patients and healthcare infrastructure across global regions. By treatment type, drug therapies dominate the landscape, accounting for 68.2% of all treatment approaches. Surgical procedures, while less common, are used in 17.4% of cases, especially in refractory or severe instances. Application segmentation shows that hospitals handle 61% of all treatment interventions, ambulatory surgical centers manage 24%, and the remaining 15% is distributed across specialty clinics and home-based care models.

By Type

Drug Treatment: Drug therapy remains the most utilized option, with over 480,000 global prescriptions in 2023. Metoclopramide, erythromycin, domperidone, ondansetron, and promethazine are the top agents used. Metoclopramide alone was prescribed to 62.5% of patients. Drug combinations have gained traction, used in 34% of moderate to severe cases. Clinical trials continue for new agents like relamorelin and tradipitant, each undergoing testing in populations exceeding 3,000 patients globally. Drug-based management reduces emergency visits in 44% of patients after three months of therapy.
Surgical Treatment: Surgical procedures accounted for 12,000 GES implants, 8,600 pyloroplasty surgeries, and 4,200 gastrostomy placements in 2023. Hospitals across the U.S., Germany, and Japan lead in surgical volume. Surgical treatment is often reserved for patients unresponsive to drugs for over 6 months, with efficacy ranging from 68%–78% based on symptom type. Minimally invasive laparoscopic options now represent 58% of total surgical interventions.

By Application

Hospital: Hospitals handle the majority of treatments, including 52,000 drug initiations, 11,000 surgical procedures, and 83,000 inpatient stays in 2023. Hospital imaging and diagnostic services also conducted over 340,000 gastric emptying scans, confirming diagnosis in 91% of submitted cases.
Ambulatory Surgical Center: These facilities performed 8,600 pyloroplasties and 3,100 GES implants. ASCs are more prominent in North America and Western Europe, contributing to faster patient turnover and lower inpatient costs by 18% compared to hospital surgeries.
Others: Specialty gastroenterology clinics and home care providers accounted for approximately 47,000 follow-ups, 68,000 medication adjustments, and 9,200 nutritional support plans, especially for patients preferring decentralized care.

Gastroparesis Treatment Market Regional Outlook

The gastroparesis treatment market presents varied adoption and prevalence patterns across global regions. Regional differences in healthcare infrastructure, diabetic population size, treatment availability, and diagnostics significantly affect treatment rates.

North America

North America dominates the global market, with over 1.9 million diagnosed cases and 83,000 hospitalizations in 2023. The region issued over 320,000 prokinetic prescriptions, and conducted 52,000 gastric electrical stimulator surgeries. Diagnostic access is strong, with 78% of suspected cases confirmed via gastric scintigraphy. Insurance coverage supports drug and surgical treatment, while ambulatory centers performed 6,400 pyloroplasties in 2023. The U.S. alone contributes 60% of global surgical procedures and 45% of medication sales in this segment.

Europe

Europe holds the second-largest share, with 1.1 million active patients. Germany, the UK, and France are key contributors, together representing over 56% of regional surgical procedures. In 2023, more than 145,000 drug prescriptions were issued across EU states, and 3,400 GES surgeries were conducted. Diagnostic rates improved, with 68% of gastroenterology clinics using breath tests or motility capsules. Regulatory support for domperidone and combination therapy protocols has driven broader acceptance in public healthcare.

Asia-Pacific

The Asia-Pacific region is growing steadily, with an estimated 1.6 million patients, primarily in China and India. In 2023, China alone reported 280,000 prescriptions, while India exceeded 190,000. Surgical procedures in Asia-Pacific were limited to 5,600 cases, due to uneven infrastructure. However, low-cost diagnostics, including wireless motility capsules used in 40,000 tests, have helped close the gap. Japan leads in surgical adoption with 2,800 gastroparesis-related interventions in 2023, including 1,400 GES implants.

Middle East & Africa

This region reported the lowest diagnosis rates, with approximately 360,000 identified patients. Diagnostic limitations mean less than 32% of suspected cases receive a confirmed diagnosis. Total annual prescriptions stood at 62,000, and surgical interventions at only 1,150 cases. South Africa, UAE, and Saudi Arabia are investing in gastroenterology training, and collectively accounted for 72% of all regional hospital-based treatments. However, treatment remains cost-prohibitive for a majority of patients, with medication access in only 49% of healthcare facilities.

List Of Gastroparesis Treatment Companies

Medtronic
Abbott
Bausch Health
Boston Scientific
R. Bard
Johnson & Johnson
Cardinal Health
Evoke Pharma
Rhythm Pharmaceuticals

Medtronic: Medtronic holds the top position in the surgical treatment segment with over 10,400 GES implants globally in 2023. Their Enterra II system is approved in over 37 countries and dominates the neuromodulation sub-segment with an 86% share in gastroparesis-related neurostimulators.

Evoke Pharma: Evoke Pharma leads the drug treatment segment with its nasal metoclopramide therapy. The company supplied medication to over 78,000 patients in 2023, with 96% reporting symptom reduction in nausea and vomiting. Their delivery method has reduced pill burden and improved patient compliance by 23%.

Investment Analysis and Opportunities

The gastroparesis treatment market has attracted increasing investment interest due to its growing global burden, with more than 5.1 million affected patients and over 460,000 new diagnoses in 2023. This rising prevalence is matched by increasing treatment demand, with 480,000 prescriptions issued globally and more than 24,000 surgical procedures performed, creating a strong base for targeted capital deployment across drug development, device innovation, and diagnostics. Pharmaceutical investment is expanding, particularly in prokinetic and ghrelin receptor agonists. Venture funding in gastrointestinal drug pipelines surpassed USD 550 million across 2023, with over 14 gastroparesis-focused compounds in mid- to late-stage trials. Companies developing novel therapies, such as relamorelin and tradipitant, are investing in clinical trials involving over 2,000 patients globally, with early results indicating 33%–41% symptom relief effectiveness, encouraging further strategic funding. The surgical device segment is another hotspot for investment. Medtronic, with over 10,400 Enterra II GES implants in 2023, has increased production capacity in its neurostimulation device line by 17% year-over-year. Investors are supporting advancements in minimally invasive surgical methods, with 24% of all GES procedures in 2023 performed laparoscopically, driving device adoption. Moreover, manufacturers are focusing on rechargeable and externally programmable GES units, meeting demands for precision therapy and cost efficiency. Digital health and diagnostics are seeing rapid funding growth. Wireless motility capsules were used in 40,000 diagnostic procedures in 2023, and over 22 digital GI monitoring platforms entered the validation phase. These platforms, often supported by artificial intelligence, improve diagnostic precision by 26% and reduce time to treatment by 19%. Funding rounds exceeding USD 180 million were closed by health-tech startups focusing on motility disorders. Investors are also allocating capital toward portable gastric mapping systems and real-time symptom tracking apps, which are used by over 18,000 patients globally.

New Product Development

In 2023 and 2024, significant innovations in gastroparesis treatment emerged across drug delivery, neuromodulation devices, and diagnostic technologies. One notable development is the nasal metoclopramide spray by Evoke Pharma, which treated 78,000 patients in 2023 and achieved a 96% efficacy rate in reducing nausea and vomiting compared with oral forms. This nasal spray reduced pill burden and improved compliance by 23% versus traditional oral therapies. Evoke’s development pipeline also includes relamorelin, a ghrelin receptor agonist currently in Phase III trials involving 1,350 patients. Early data indicate a 41% symptom reduction and a 33% improvement in gastric emptying rate. Another innovation is tradipitant, a neurokinin-1 receptor antagonist tested in 820 patients, showing 37% reduction in nausea frequency compared to placebo. In the surgical space, Medtronic introduced Enterra II with enhanced lead design and rechargeable neurostimulator, receiving approval in 12 new countries, bringing total geographies to 37 by 2024. Over 10,400 units were implanted, reducing device failures by 27% compared to earlier models. Additionally, a minimally invasive laparoscopic approach for GES insertion has been adopted in 24% of new surgeries, reducing recovery time by 31% and hospital stay by 1.8 days.

Diagnostic-focused innovations include wireless motility capsules used in 40,000 tests in 2023 in Asia-Pacific, offering real-time data on gastric transit with accuracy rates of 91%. Breath testing technology expanded in Europe to 68% of gastroenterology centers, improving early detection rates by 18%. Smart algometry devices for symptom tracking were piloted with 22,000 patients; these tools enhanced symptom logging by 44%, helping physicians adjust therapy more precisely. Nutrition-related innovations include blenderized feeding pump systems approved for home use in 9,200 patients in 2023. These systems reduced tube feeding complications by 29% and delivered 72% of daily nutritional requirements. A combination therapy of botulinum toxin pyloric injections showed symptom improvement in 38% of 540 treated patients, with effects lasting 16 weeks, reducing the need for surgical referral. Additionally, clinical research introduced transcutaneous electrical nerve stimulation patches tested on 15,000 patients, demonstrating a 26% reduction in bloating and nausea episodes. These new patch devices are now used in 18% of refractory cases due to their non-invasive nature and symptom affordability. These product developments—ranging from nasal sprays and ghrelin agonists to nerve stimulation patches and motility diagnostics—are reshaping gastroparesis care by offering customizable, minimally invasive, and patient-centric treatment options that address compliance and symptom control.

Five Recent Developments

Evoke Pharma expanded nasal metoclopramide spray use to 78,000 patients by late 2023, improving compliance by 23% compared to pills.
Medtronic released Enterra II neurostimulator, approved in 12 additional countries, bringing total implant count to 10,400 units.
Relamorelin Phase III trial enrolled 1,350 patients, showing 41% symptom reduction and 33% improved gastric emptying.
Wireless motility capsules used in 40,000 Asian patients in 2023, delivering real-time transit data with 91% diagnostic accuracy.
Minimally invasive GES surgery adoption rose to 24% of implants, reducing hospitalization by 1.8 days and recovery by 31%.

Report Coverage of Gastroparesis Treatment Market

This comprehensive gastroparesis treatment market report examines prevalence, diagnostic pathways, treatment modalities, key players, product innovation, regional distribution, investment trends, and future outlook. Patient prevalence data reveal over 5.1 million individuals worldwide, including 1.9 million in North America, 1.1 million in Europe, 1.6 million in Asia-Pacific, and 0.36 million in the Middle East & Africa. Diabetic subgroups feature high diagnostic rates, with 25.3% of type 1 and 13.6% of type 2 patients affected. The global healthcare burden includes 83,000 hospitalizations, 124,000 emergency visits, and 31.6 hospitalizations per 100,000 persons annually in North America. Treatment segmentation is thoroughly explored. Drug therapy accounted for 68.2% of interventions, showcasing 480,000 prescriptions of prokinetics and antiemetics such as metoclopramide, erythromycin, ondansetron, and promethazine. The drug segment also encompasses traditional agents and emerging pipeline molecules like relamorelin and tradipitant in trials with 1,350 and 820 patients respectively. Surgical interventions, primarily gastric electrical stimulation (GES), pyloroplasty, and gastrostomy, constitute 17.4% of cases, with 12,000 Enterra II implants, 8,600 pyloroplasties, and 4,200 gastrostomies conducted in 2023. Minimally invasive surgeries now make up 58% of all surgical procedures. Diagnosis methodology analysis addresses gastric emptying scintigraphy (used in 55% of cases), wireless motility capsules (16% of diagnostics), breath tests (68% adoption in Europe), and electrogastrography applied in research protocols. This report outlines diagnostic timelines, revealing averages of 2.3 years from symptom onset to confirmed diagnosis and diagnostic volumes of 340,000 scintigraphy scans in hospitals. Regional performance includes granular data: North America leads in prevalence and treatment volume, issuing 320,000 prokinetic scripts, 83,000 hospitalizations, and 52,000 GES surgeries. Europe had 1.1 million patients, 145,000 prescriptions, and 3,400 GES implants. Asia-Pacific reported 280,000 prescriptions in China, 190,000 in India, 5,600 total surgeries, and 40,000 motility tests. Middle East & Africa data indicate 62,000 prescriptions and 1,150 surgeries, with diagnostic programs in 49% of facilities. Competitive landscape focuses on key companies: Medtronic retains dominance in surgical devices with 10,400 implants and 86% market share, while Evoke Pharma leads drug treatment with 78,000 patients using nasal therapy. Bausch Health, Abbott, Boston Scientific, J&J, C.R. Bard, Cardinal Health, and Rhythm Pharmaceuticals are profiled for their market roles. Product innovation details are provided: nasal sprays, ghrelin agonists, enhanced neuromodulators, wireless motility capsule expansion, TENS devices, nutritional systems, and minimally invasive implants. Clinical metrics include 91% capsule diagnostic accuracy, 26% symptom reduction via patch therapy, 41% symptomatic relief in relamorelin trials, and 33% physiological improvement in gastric emptying. Operational trends analyze hospitalizations, readmission rates (28%), healthcare burden, and accessibility challenges in developing regions. Investment analysis covers device R&D, clinical trials, health tech funding for digital diagnostics, and manufacturing of neurostimulation systems. Finally, the report delves into patient pathways, clinical guidelines, diagnostic standards, and reimbursement structures across North America, Europe, Asia-Pacific, and Middle East & Africa. It offers insights for stakeholders—manufacturers, healthcare providers, payers, and investors—on opportunities, constraints, and strategic direction in the gastroparesis treatment landscape.